Vancomycin-Teixobactin Conjugates
Tech ID: 34185 / UC Case 2025-774-0
Brief Description
A novel approach to significantly enhance vancomycin's effectiveness against drug-resistant pathogens by conjugating it with a minimal teixobactin pharmacophore.
Full Description
This technology involves the conjugation of vancomycin, a critical last-resort antibiotic, with a minimal teixobactin pharmacophore, targeting a different region of lipid II to rescue and enhance its antibiotic activity. This innovative approach has resulted in the creation of conjugates that demonstrate substantial activity improvements against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), and even vancomycin-resistant Enterococci (VRE), where both individual components alone were ineffective.
Advantages
- Significant enhancement in antibiotic activity against Gram-positive bacteria.
- Effective against drug-resistant strains such as MRSA and VRE.
- Offers a new life to vancomycin by overcoming resistance mechanisms.
- Does not require the discovery of new antibiotics, but rather improves existing ones.
- Provides a strategic approach to combating antibiotic resistance.
Suggested uses
- Healthcare industry, particularly in the development of treatments for drug-resistant bacterial infections.
- Pharmaceutical companies focused on antibiotic research and development.
- Hospitals and clinics dealing with high rates of MRSA, MSSA, and VRE infections.
- Public health initiatives aimed at controlling the spread of antibiotic-resistant bacteria.
Patent Status
Patent Pending
Related Materials